Please assess the completion status of the following clinical trial:

Trial Title: MMR Vaccination Among HIV-infected Adults

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~For HIV-infected participants, inclusions criteria were~1. 20-59 years old, ability to provide informed consent~2. receiving cART~3. CD4 cell count ≥200 cell/mm3 within 6 months before enrollment~4. plasma HIV-1 RNA \<50 copies/mL, and 5) ability to provide informed consent.~Exclusion Criteria:~For both groups~1. pregnancy or lactating~2. receiving cancer treatment, organ transplantation, ≥0.5 mg/kg/day of prednisolone or equivalent, or immunomodulating treatment~3. impaired renal function (creatinine clearance \<30 mL/min)~4. impaired liver function as defined by Child-Pugh C.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 59 Years
- Healthy Volunteers: t

Study Arms:
- HIV-infected adults (Type: ACTIVE_COMPARATOR): Two-hundreds and forty-nine HIV-infected participants received a single dose of MMR vaccine (GlaxoSmithKline Biologicals) at deltoid region.~Interventions were a single dose of 0.5 ml of MMR vaccine. Each 0.5 ml of vaccine contained at least 1000 TCID50 of Schwarz measles strain, at least 1000 TCID50 of RIT 4385 mumps, and at least 1000 TCID50 of Wistar RA 27/3 rubella strains.
- HIV-uninfected adults (Type: EXPERIMENTAL): Forty-six HIV-uninfected participants received a single dose of MMR vaccine (GlaxoSmithKline Biologic) at deltoid region.~Interventions were a single dose of 0.5 ml of MMR vaccine. Each 0.5 ml of vaccine contained at least 1000 TCID50 of Schwarz measles strain, at least 1000 TCID50 of RIT 4385 mumps, and at least 1000 TCID50 of Wistar RA 27/3 rubella strains.

Based on this trial design, predict the completion outcome and termination type (if applicable).